Key Points
- ResMed director Peter Farrell sold 8,000 shares at an average price of $225, generating $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 plan, and Farrell retained 52,773 shares.
- ResMed reported quarterly EPS of $2.95, beating the $2.89 consensus, while revenue totaled $1.46 billion, up 8.6% year over year and in line with estimates.
- Analyst sentiment remains mixed: seven analysts rate the stock a Buy and nine rate it a Hold, producing a consensus Hold rating and a $246.25 target price versus the stock’s $223.77 opening price.
ResMed Inc. (NYSE:RMD - Get Free Report) Director Peter Farrell sold 8,000 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total value of $1,800,000.00. Following the completion of the sale, the director owned 52,773 shares of the company's stock, valued at $11,873,925. This trade represents a 13.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ResMed Trading Down 0.1%
Shares of NYSE:RMD opened at $223.77 on Friday. ResMed Inc. has a 1 year low of $180.26 and a 1 year high of $293.81. The firm has a market capitalization of $32.46 billion, a price-to-earnings ratio of 21.58, a price-to-earnings-growth ratio of 1.36 and a beta of 0.76. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33. The business's 50 day moving average price is $200.06 and its 200-day moving average price is $222.30.
ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.89 by $0.06. The firm had revenue of $1.46 billion for the quarter, compared to analysts' expectations of $1.46 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The firm's revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.55 EPS. On average, equities research analysts forecast that ResMed Inc. will post 11.14 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on RMD shares. Mizuho dropped their target price on shares of ResMed from $235.00 to $220.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 15th. KeyCorp reduced their price target on shares of ResMed from $290.00 to $266.00 and set an "overweight" rating for the company in a research report on Monday, June 22nd. Robert W. Baird set a $225.00 price target on shares of ResMed in a research note on Friday, May 1st. Jefferies Financial Group lowered their price objective on ResMed from $240.00 to $225.00 and set a "hold" rating on the stock in a report on Friday, July 10th. Finally, Weiss Ratings lowered ResMed from a "hold (c)" rating to a "hold (c-)" rating in a research note on Friday, July 24th. Seven research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, ResMed has a consensus rating of "Hold" and a consensus target price of $246.25.
Get Our Latest Research Report on ResMed
More ResMed News
Here are the key news stories impacting ResMed this week:
- Positive Sentiment: ResMed reported fiscal Q4 earnings of $2.95 per share, exceeding the approximately $2.89–$2.90 analyst consensus and rising from $2.55 a year earlier. Revenue reached $1.46 billion, in line with estimates and up 8.6% year over year, supporting the company’s growth narrative. ResMed Q4 Earnings and Revenues Top Estimates
- Positive Sentiment: The company also announced a dividend increase alongside strong fourth-quarter and full-year fiscal 2026 results, potentially improving the stock’s appeal to income-oriented investors. ResMed Reports Strong Q4 Results and Dividend Increase
- Positive Sentiment: Management’s earnings call follows a quarter with a 27.44% net margin and 25.35% return on equity, indicating continued profitability and operating strength. ResMed Q4 2026 Earnings Call Transcript
- Neutral Sentiment: Analyst views on ResMed remain mixed, which may be limiting the market’s reaction despite the earnings beat. Earlier previews also highlighted tariff, inflation and hospital-spending risks facing medtech companies. Analysts Have Conflicting Sentiments on ResMed
- Negative Sentiment: Director Peter C. Farrell sold 8,000 shares worth $1.8 million. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, reducing its signaling value, but it may still add modest short-term selling pressure. SEC Insider Trading Filing
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC raised its stake in ResMed by 17.6% during the fourth quarter. Hsbc Holdings PLC now owns 328,785 shares of the medical equipment provider's stock worth $79,321,000 after purchasing an additional 49,253 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of ResMed by 13.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 979,087 shares of the medical equipment provider's stock valued at $235,833,000 after buying an additional 118,296 shares during the period. Fideuram Asset Management Ireland dac purchased a new stake in shares of ResMed in the 4th quarter valued at approximately $4,712,000. Legal & General Group Plc increased its holdings in shares of ResMed by 3.6% during the 4th quarter. Legal & General Group Plc now owns 992,527 shares of the medical equipment provider's stock worth $239,070,000 after buying an additional 34,317 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of ResMed by 23.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,810 shares of the medical equipment provider's stock worth $5,735,000 after buying an additional 4,541 shares during the last quarter. Hedge funds and other institutional investors own 54.98% of the company's stock.
About ResMed
(
Get Free Report)
ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.
ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
